Clinical Radiology
Volume 65, Issue 7 , Pages 536-548 , July 2010

Non FDG PET

  • C. Nanni

      Affiliations

    • Corresponding Author InformationGuarantor and correspondent: C. Nanni, UO Medicina Nucleare, Ospedale S.Orsola-Malpighi, Via Massarenti n.9, 40138 Bologna, Italy. Tel.: +39(0) 51 6363187.
    • ,
  • L. Fantini
    • ,
  • S. Nicolini
    • ,
  • S. Fanti

Received 30 October 2009 ,Revised 9 March 2010 ,Accepted 15 March 2010.

References 

  1. Prévost A, Papathanassiou D, Jovenin N, et al. Comparison between PET(-FDG) and computed tomography in the staging of lung cancer. Consequences for operability in 94 patients. Rev Pneumol Clin. 2009;65:341–349
  2. Aukema TS, Rutgers EJ, Vogel WV, et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol. 2010;36(4):387–392
  3. Meignan M, Itti E, Gallamini A, et al. Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation—where do we stand?. Leuk Lymphoma. 2009;50:1753–1756
  4. Furth C, Steffen IG, Amthauer H, et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin’s lymphoma: analysis of a prospective multicenter trial. J Clin Oncol. 2009;27:4385–4391
  5. Crocchiolo R, Fallanca F, Giovacchini G, et al. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin’s lymphoma. Ann Hematol. 2009;88:1229–1236
  6. Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27:1781–1787
  7. Lim SM, Katsifis A, Villemagne VL, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50:1638–1645
  8. Noble JM, Scarmeas N. Application of pet imaging to diagnosis of Alzheimer’s disease and mild cognitive impairment. Int Rev Neurobiol. 2009;84:133–149
  9. Bengel FM, Higuchi T, Javadi MS, et al. Cardiac positron emission tomography. J Am Coll Cardiol. 2009;54:1–15
  10. Sanz G, Robles JE, Giménez M, et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int. 1999;84:1028–1031
  11. Kayani I, Conry BG, Groves AM, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50:1927–1932
  12. Hwang KH, Choi DJ, Lee SY, et al. Evaluation of patients with hepatocellular carcinomas using [ (11)C]acetate and [ (18)F]FDG PET/CT: a preliminary study. Appl Radiat Isot. 2009;67:1195–1198
  13. Basu S, Alavi A. Molecular imaging (PET) of brain tumors. Neuroimaging Clin N Am. 2009;19:625–646
  14. Perko R, Messinger Y, Moertel C. Pseudometastasis secondary to histoplasmosis infection: false-positive PET/CT findings. Pediatr Blood Cancer. 2010;54(4):621–623
  15. Ponnuswamy A, Mediratta N, Lyburn ID, et al. False positive diagnosis of malignancy in a case of cryptogenic organising pneumonia presenting as a pulmonary mass with mediastinal nodes detected on fluorodeoxyglucose-positron emission tomography: a case report. J Med Case Reports. 2009;3:124
  16. Bertagna F, Giubbini R, Biasiotto G, et al. Incidental inflammatory findings in nerves and in patients with neoplastic diseases evaluated by (18)F-FDG-PET/CT. Hell J Nucl Med. 2009;12:279–280
  17. Camici PG, Rimoldi OE. The clinical value of myocardial blood flow measurement. J Nucl Med. 2009;50:1076–1087Epub 2009 Jun 12
  18. Sanz G, Rioja J, Zudaire JJ, et al. PET and prostate cancer. World J Urol. 2004;22:351–352
  19. Picchio M, Messa C, Landoni C, et al. Value of [11C]choline positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol. 2003;169:1337–1340
  20. Picchio M, Landoni C, Messa C, et al. Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol. 2002;179:482–484
  21. de Jong IJ, Pruim J, Elsinga PH, et al. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003;44:32–38
  22. Castellucci P, Fuccio C, Nanni C, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394–1400
  23. Farsad M, Schiavina R, Castellucci P, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642–1649
  24. Nanni C, Zamagni E, Cavo M, et al. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol. 2007;5:68
  25. Kwee SA, Coel MN, Lim J, et al. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 2005;173:252–255
  26. Kwee SA, Wei H, Sesterhenn I, et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006;47:262–269
  27. Kwee SA, Thibault GP, Stack RS, et al. Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer. Mol Imaging. 2008;7:12–20
  28. Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml?. Mol Imaging Biol. 2006;8:43
  29. Cimitan M, Bortolus R, Morassut S, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387–1398Epub 2006 Jul 25
  30. Scher B, Seitz M. PET/CT imaging of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:5–8
  31. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005;235:623–628
  32. Reske SN, Blumstein NM, Neumaier B, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med. 2006;47:1249–1254
  33. Talbot JN, Gutman F, Fartoux L. PET/CT in patients with hepatocellular carcinoma using [ (18)F]fluorocholine: preliminary comparison with [ (18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006;33:1285–1289
  34. Pirotte B, Goldman S, Dewitte O, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006;104:238–253
  35. Price SJ. The role of advanced MR in understanding brain tumors pathology. Br J Neurosurg. 2007;21:562–575
  36. Kim Sungeun, Chung June-Key, Im So-Hyang, et al. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005;2:52–59
  37. Van Laere K, Ceyssens S, Van Calenbergh F, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32:39–51
  38. Herholz K, Hölzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316–1322
  39. De Witte O, Goldberg I, Wikler D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg. 2001;95:746–750
  40. Ribom D, Eriksson A, Hartman M, et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer. 2001;92:1541–1549
  41. Smits A, Westerberg E, Ribom D. Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas. Eur J Nucl Med Mol Imaging. 2008;35:65–71
  42. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778–785
  43. Sadeghi N, Salmon I, Tang BN, et al. Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results. J Magn Reson Imaging. 2006;24:989–994
  44. Pirotte B, Goldman S, Massager N, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004;45:1293–1298
  45. Geetsa X, Daisnea J-F, Gregoirea V, et al. Role of 11-C-methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma: comparison with FDG-PET and CT. Radiother Oncol. 2004;71:267–273
  46. Rubello D, Fanti S, Nanni C, et al. 11C-methionine PET/CT in 99mTc-sestamibi-negative hyperparathyroidism in patients with renal failure on chronic haemodialysis. Eur J Nucl Med Mol Imaging. 2006;33:453–459
  47. Otto D, Boerner AR, Hofmann M, et al. Pre-operative localisation of hyperfunctional parathyroid tissue with 11C-methionine PET. Eur J Nucl Med Mol Imaging. 2004;31:1405–1412
  48. Sundin A, Johansson C, Hellman P, et al. PET and parathyroid L-[carbon-11]methionine accumulation in hyperparathyroidism. J Nucl Med. 1996;37:1766–1770
  49. Beggs AD, Hain SF. Localization of parathyroid adenomas using 11C-methionine positron emission tomography. Nucl Med Commun. 2005;26:133–136
  50. Tang BN, Moreno-Reyes R, Blocklet D, et al. Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT. Contrast Media Mol Imaging. 2008;3:157–163
  51. Herrmann K, Takei T, Kanegae K, et al. Clinical value and limitations of [11C]-methionine PET for detection and localization of suspected parathyroid adenomas. Mol Imaging Biol. 2009;11:356–363
  52. Ahlstrom H, Eriksson B, Bergstrom M, et al. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology. 1995;195:333–337
  53. Hoegerle S, Altehoefer C, Ghanem N, et al. Whole-body 18F DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology. 2001;220:373–380
  54. Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: detection with 18F DOPA whole body PET—initial results. Radiology. 2002;222:507–512
  55. Hoegerle S, Ghanem N, Altehoefer C, et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003;30:689–694
  56. Brink I, Hoegerle S, Klisch J, et al. Imaging of pheochromocytoma and paraganglioma. Fam Cancer. 2005;4:61–68
  57. Hoegerle S, Altehoefer C, Ghanem N, et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64–71
  58. de Vries EFJ, Luurtsema G, Brussermann M, et al. Fully automated synthesis module for the high yield one-pot preparation of 6- [18F]fluoro-L-DOPA. Appl Radiat Isotopes. 1999;51:389–394
  59. Eshuis SA, Maguire RP, Leenders KL, et al. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2006;33:200–209
  60. Leenders KL, Salmon EP, Tyrrell P, et al. The nigro-striatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson’s Disease. Arch Neurol. 1990;47:1290–1298
  61. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry. 1986;49:853–860
  62. Goodman MM, Keil R, Shoup TM, et al. Fluorine-18-FPCT: a PET radiotracer for imaging dopamine transporters. J Nucl Med. 1997;38:119–126
  63. Zigmond MJ, Abercrombie ED, Berger TW, et al. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990;13:290–296
  64. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46:62S–66S
  65. Wild D, Mäcke HR, Waser B, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724
  66. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338–1347
  67. Ginj M, Chen J, Walter MA, et al. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res. 2005;11:1136–1145
  68. Ambrosini V, Tomassetti P, Castellucci P, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431–1438Epub 2008 Apr 17
  69. Antunes P, Ginj M, Zhang H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging. 2007;34:982–993
  70. Dimitrakopoulou-Strauss A, Strass LG. PET imaging of prostate cancer with 11C-acetate. J Nucl Med. 2003;44:4
  71. Delbeke D, Wright Pinson C. 11C-acetate: a new tracer for the evaluation of hepatocellular carcinoma. J Nucl Med. 2003;44:2
  72. Park JW, Kim JH, Kim SK, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912–1921
  73. Been Lukas B, Suurmeijer Albert JH, et al. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 2004;31:1559–1672
  74. Buck Andreas K, Herrmann Ken, Shen Changxian, et al. Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine. Methods. 2009;205–215
  75. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med. 2008;49:64S–80S
  76. Vallabhajosula S. 18F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med; 37:400–419.
  77. Shields AF. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol. 2006;8:141–150
  78. Krohn KA, Mankoff DA, Muzi M, et al. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol. 2005;32:663–671
  79. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol. 2001;41:96S–103S
  80. Larson SM, Schoder H. New PET tracers for evaluation of solid tumors response to therapy. Q J Nucl Med Mol Imaging. 2009;53:158–166
  81. Beheshti M, Vali R, Langsteger W. [18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:1316–1317
  82. Lewis JS, Welch MJ. PET imaging of hypoxia. Q J Nucl Med. 2001;45:183–188
  83. Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med. 1996;37:1701–1712
  84. Beanlands RS, Muzik O, Hutchins GD, et al. Heterogeneity of regional nitrogen 13-labeled ammonia tracer distribution in the normal human heart: comparison with rubidium 82 and copper 62-labeled PTSM. J Nucl Cardiol. 1994;1:225–235
  85. Dobrucki LW, Sinusas AJ. Cardiovascular molecular imaging. Semin Nucl Med. 2005;35:73–81
  86. Herrero P, Kim J, Sharp TL, et al. Assessment of myocardial blood flow using 15O-water and 1-11C-acetate in rats with small-animal PET. J Nucl Med. 2006;47:477–485
  87. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med. 2006;47:2048–2056
  88. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm. 2006;3:472–487
  89. Cauchon N, Langlois R, Rousseau JA, et al. PET imaging of apoptosis with 64Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V. Eur J Nucl Med Mol Imaging. 2007;34:247–258
  90. Yaghoubi SS, Couto MA, Chen CC, et al. Preclinical safety evaluation of 18F-FHBG: a PET reporter probe for imaging herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk’s expression. J Nucl Med. 2006;47:706–715
  91. Weckesser M, Langen KJ, Rickert CH, et al. O-(2- [ (18)F]fluoroethyl)-l-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging. 2005;32:422–429
  92. Bader JB, Samnick S, Moringlane JR, et al. Evaluation of l-3- [123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med. 1999;26:144–151
  93. Weber WA, Wester HJ, Grosu AL, et al. O-(2- [18F]fluoroethyl)- l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000;27:542–549
  94. Floeth FW, Pauleit D, Sabel M, et al. Prognostic value of O-(2-18F-fluoroethyl)- l-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007;48:519–527
  95. Mehrkens JH, Popperl G, Rachinger W, et al. The positive predictive value of O-(2- [18F]fluoroethyl)- l-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol. 2008;88:27–35
  96. Floeth FW, Sabel M, Stoffels G, et al. Prognostic value of 18F-fluoroethyl- l-tyrosine PET and MRI in small nonspecific incidental brain lesions. J Nucl Med. 2008;49:730–737

PII: S0009-9260(10)00179-0

doi: 10.1016/j.crad.2010.03.012

Clinical Radiology
Volume 65, Issue 7 , Pages 536-548 , July 2010

Article Tools

* Image Usage & Resolution